Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2012 1
2013 3
2014 3
2015 1
2016 5
2017 3
2018 6
2019 10
2020 7
2021 7
2022 5
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.
Siu LL, Wang D, Hilton J, Geva R, Rasco D, Perets R, Abraham AK, Wilson DC, Markensohn JF, Lunceford J, Suttner L, Siddiqi S, Altura RA, Maurice-Dror C. Siu LL, et al. Among authors: hilton j. Clin Cancer Res. 2022 Jan 1;28(1):57-70. doi: 10.1158/1078-0432.CCR-21-2160. Epub 2021 Oct 1. Clin Cancer Res. 2022. PMID: 34598945 Free PMC article.
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, Im SA, Kim SB, Johnston SR, Chan A, Goel S, Catron K, Chapman SC, Price GL, Yang Z, Gainford MC, André F. Tolaney SM, et al. Among authors: hilton jf. Lancet Oncol. 2020 Jun;21(6):763-775. doi: 10.1016/S1470-2045(20)30112-1. Epub 2020 Apr 27. Lancet Oncol. 2020. PMID: 32353342 Clinical Trial.
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI. Patnaik A, et al. Among authors: hilton jf. Cancer Discov. 2016 Jul;6(7):740-53. doi: 10.1158/2159-8290.CD-16-0095. Epub 2016 May 23. Cancer Discov. 2016. PMID: 27217383
Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT).
Basulaiman B, Awan AA, Fergusson D, Vandermeer L, Arnaout A, Hilton J, Hutton B, Joy AA, Robinson A, Califaretti N, Stober C, Sienkiewicz M, Thavorn K, Clemons M. Basulaiman B, et al. Among authors: hilton j. Breast Cancer Res Treat. 2019 Aug;177(1):93-101. doi: 10.1007/s10549-019-05274-0. Epub 2019 May 24. Breast Cancer Res Treat. 2019. PMID: 31127468 Review.
A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer.
Cescon DW, Hilton J, Morales Murilo S, Layman RM, Pluard T, Yeo B, Park IH, Provencher L, Kim SB, Im YH, Wyce A, Krishnatry AS, Hicks K, Zhang Q, Barbash O, Khaled A, Horner T, Dhar A, Oliveira M, Sparano JA. Cescon DW, et al. Among authors: hilton j. Clin Cancer Res. 2024 Jan 17;30(2):334-343. doi: 10.1158/1078-0432.CCR-23-0133. Clin Cancer Res. 2024. PMID: 37992310 Free PMC article. Clinical Trial.
Poly(ADP-ribose) polymerase inhibitors as cancer therapy.
Hilton JF, Hadfield MJ, Tran MT, Shapiro GI. Hilton JF, et al. Front Biosci (Landmark Ed). 2013 Jun 1;18(4):1392-406. doi: 10.2741/4188. Front Biosci (Landmark Ed). 2013. PMID: 23747892 Free article. Review.
51 results